Compare Gerdau S.A. Common Stock (GGB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gerdau S.A. Common Stock vs Tango Therapeutics Inc. — how do they compare? Gerdau S.A. Common Stock trades at $5.15 (market cap $9.66B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Gerdau S.A. Common Stock is far larger — about 2.6× Tango Therapeutics Inc.'s market cap, and Gerdau S.A. Common Stock pays a 3.48% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| GGB | TNGX | |
|---|---|---|
Market Cap | $9.66B | $3.75B |
Volume | 9,572,970 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $5.18 | $32.90 |
52-Week Low | $3.25 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.61B | $2.77B |
Dividend Yield | 3.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gerdau (GGB) trades at $5.18, up 0.78% with strong technical momentum and bullish moving average signals. The company reported mixed Q2 2026 earnings meeting expectations but missed previous quarters, while showing improved profitability with net income margin expanding to 3.23%. Recent news highlights institutional buying interest and dividend appeal, with the stock approaching its 52-week high of $5.48.
GGB presents a value opportunity with attractive valuation multiples (P/S 0.73, P/B 0.95) and strong analyst support (70% buy ratings). However, recent earnings misses and competitive pressures in Brazilian operations pose execution risks. The improving cash flow trajectory and institutional accumulation suggest potential upside if operational improvements continue.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gerdau S.A. Common Stock
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
